1. BarnesPM, BloomB, NahinRL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report2008;(12):1.

2. LavineJE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr2000;136:734. CrossRef

3. HillDB, DevalarajaR, Joshi‐BarveS, et al.Antioxidants attenuate nuclear factor‐kappa B activation and tumor necrosis factor‐alpha production in alcoholic hepatitis patient monocytes and rat Kupffer cells, in vitro. Clin Biochem1999;32:563. CrossRef

4. Abdel‐AzeemAS, HegazyAM, IbrahimKS, et al.Hepatoprotective, antioxidant, and ameliorative effects of ginger (Zingiber officinale Roscoe) and vitamin E in acetaminophen treated rats. J Diet Suppl2013;10:195. CrossRef

5. HasegawaT, YonedaM, NakamuraK, et al.Plasma transforming growth factor‐beta1 level and efficacy of alpha‐tocopherol in patients with non‐alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther2001;15:1667. CrossRef

6. LavineJE, SchwimmerJB, Van NattaML, et al.Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA2011;305:1659. CrossRef

7. MussoG, GambinoR, CassaderM, et al.A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology2010;52:79. CrossRef

8. SanyalAJ, ChalasaniN, KowdleyKV, et al.Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med2010;362:1675. CrossRef

9. BellLN, WangJ, MuralidharanS, et al.Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow‐up study. Hepatology2012;56:1311. CrossRef

10. HanjeAJ, FortuneB, SongM, et al.The use of selected nutrition supplements and complementary and alternative medicine in liver disease. Nutr Clin Pract2006;21:255. CrossRef

11. SongZ, DeaciucI, SongM, et al.Silymarin protects against acute ethanol‐induced hepatotoxicity in mice. Alcohol Clin Exp Res2006;30:407. CrossRef

12. FerenciP, DragosicsB, DittrichH, et al.Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol1989;9:105. CrossRef

13. ParesA, PlanasR, TorresM, et al.Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double‐blind, randomized and multicenter trial. J Hepatol1998;28:615. CrossRef

14. JacobsBP, DennehyC, RamirezG, et al.Milk thistle for the treatment of liver disease: a systematic review and meta‐analysis. Am J Med2002;113:506. CrossRef

15. RambaldiA, JacobsBP, IaquintoG, et al.Milk thistle for alcoholic and/or hepatitis B or C liver diseases–a systematic cochrane hepato‐biliary group review with meta‐analyses of randomized clinical trials. Am J Gastroenterol2005;100:2583. CrossRef

16. CraigSA. Betaine in human nutrition. Am J Clin Nutr2004;80:539.

17. AbdelmalekMF, AnguloP, JorgensenRA, et al.Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol2001;96:2711. CrossRef

18. AbdelmalekMF, SandersonSO, AnguloP, et al.Betaine for nonalcoholic fatty liver disease: results of a randomized placebo‐controlled trial. Hepatology2009;50:1818. CrossRef

19. MeisterA. New developments in glutathione metabolism and their potential application in therapy. Hepatology1984;4:739. CrossRef

20. MarzulloL. An update of N‐acetylcysteine treatment for acute acetaminophen toxicity in children. Curr Opin Pediatr2005;17:239. CrossRef

21. PenaLR, HillDB, McClainCJ. Treatment with glutathione precursor decreases cytokine activity. JPEN J Parenter Enteral Nutr1999;23:1. CrossRef

22. IimuroY, BradfordBU, YamashinaS, et al.The glutathione precursor L‐2‐oxothiazolidine‐4‐carboxylic acid protects against liver injury due to chronic enteral ethanol exposure in the rat. Hepatology2000;31:391. CrossRef

23. LieberCS. Pathogenesis and treatment of alcoholic liver disease: progress over the last 50 years. Rocz Akad Med Bialymst2005;50:7.

24. LieberCS, WeissDG, GroszmannR, et al.II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res2003;27:1765. CrossRef

25. GhoshN, GhoshR, MandalV, et al.Recent advances in herbal medicine for treatment of liver diseases. Pharm Biol2011;49:970. CrossRef

26. van RossumTG, VultoAG, HopWC, et al.Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double‐blind, randomized, placebo‐controlled phase I/II trial. J Gastroenterol Hepatol1999;14:1093. CrossRef

27. AraseY, IkedaK, MurashimaN, et al.The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer1997;79:1494. CrossRef

28. van RossumTG, de JongFH, HopWC, et al.“Pseudo‐aldosteronism” induced by intravenous glycyrrhizin treatment of chronic hepatitis C patients. J Gastroenterol Hepatol2001;16:789. CrossRef

29. McClainCJ, AntonowDR, CohenDA, et al.Zinc metabolism in alcoholic liver disease. Alcohol Clin Exp Res1986;10:582. CrossRef

30. RedingP, DuchateauJ, BatailleC. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. Lancet1984;2:493. CrossRef

31. BrewerGJ, DickRD, JohnsonVD, et al.Treatment of Wilson's disease with zinc: XV long‐term follow‐up studies. J Lab Clin Med1998;132:264. CrossRef

32. GabreyesAA, AbbasiHN, ForbesKP, et al.Hypocupremia associated cytopenia and myelopathy: a national retrospective review. Eur J Haematol2013;90:1. CrossRef

33. YangF, de VilliersWJ, McClainCJ, et al.Green tea polyphenols block endotoxin‐induced tumor necrosis factor‐production and lethality in a murine model. J Nutr1998;128:2334.

34. SakaidaI, MatsumuraY, AkiyamaS, et al.Herbal medicine Sho‐saiko‐to (TJ‐9) prevents liver fibrosis and enzyme‐altered lesions in rat liver cirrhosis induced by a choline‐deficient L‐amino acid‐defined diet. J Hepatol1998;28:298. CrossRef

35. WangL, WangJ, WangBE, et al.Effects of herbal compound 861 on human hepatic stellate cell proliferation and activation. World J Gastroenterol2004;10:2831. CrossRef

36. BrownA, HughesM, TennerS, et al.Does pancreatic enzyme supplementation reduce pain in patients with chronic pancreatitis: a meta‐analysis. Am J Gastroenterol1997;92:2032.

37. WarshawAL, BanksPA, Fernandez‐Del CastilloC. AGA technical review: treatment of pain in chronic pancreatitis. Gastroenterology1998;115:765. CrossRef

38. KaptchukTJ. Acupuncture: theory, efficacy, and practice. Ann Intern Med2002;136:374. CrossRef

39. BirchSJ, FeltRL. Understanding Acupuncture. Edinburgh; New York: Churchill Livingstone; 1999.

40. BallegaardS, ChristophersenSJ, DawidsSG, et al.Acupuncture and transcutaneous electric nerve stimulation in the treatment of pain associated with chronic pancreatitis. A randomized study. Scand J Gastroenterol1985;20:1249. CrossRef

41. GeHY, ChenB. [Clinical observation of acute pancreatitis treated with acupoint application combined with medicine]. Zhongguo Zhen Jiu2012;32:602.

42. FarrellJJ, ZhangL, ZhouH, et al.Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut2012;61:582. CrossRef

43. BesselinkMG, van SantvoortHC, BuskensE, et al.Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double‐blind, placebo‐controlled trial. Lancet2008;371:651. CrossRef

44. Expression of concern–Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double‐blind, placebo‐controlled trial. Lancet2010;375:875. CrossRef

45. GuyanPM, UdenS, BraganzaJM. Heightened free radical activity in pancreatitis. Free Radic Biol Med1990;8:347. CrossRef

46. SchoenbergMH, BuchlerM, PietrzykC, et al.Lipid peroxidation and glutathione metabolism in chronic pancreatitis. Pancreas1995;10:36. CrossRef

47. VerlaanM, RoelofsHM, van‐SchaikA, et al.Assessment of oxidative stress in chronic pancreatitis patients. World J Gastroenterol2006;12:5705.

48. Morris‐StiffGJ, BowreyDJ, OleeskyD, et al.The antioxidant profiles of patients with recurrent acute and chronic pancreatitis. Am J Gastroenterol1999;94:2135. CrossRef

49. MathewP, WyllieR, Van LenteF, et al.Antioxidants in hereditary pancreatitis. Am J Gastroenterol1996;91:1558.

50. BowreyDJ, Morris‐StiffGJ, PuntisMC. Selenium deficiency and chronic pancreatitis: disease mechanism and potential for therapy. HPB Surg1999;11:207; discussion 215. CrossRef

51. UdenS, BiltonD, NathanL, et al.Antioxidant therapy for recurrent pancreatitis: placebo‐controlled trial. Aliment Pharmacol Ther1990;4:357. CrossRef

52. De las Heras CastanoG, Garcia de la PazA, FernandezMD, et al.Use of antioxidants to treat pain in chronic pancreatitis. Rev Esp Enferm Dig2000;92:375.

53. ShahNS, MakinAJ, SheenAJ, et al.Quality of life assessment in patients with chronic pancreatitis receiving antioxidant therapy. World J Gastroenterol2010;16:4066. CrossRef

54. BhardwajP, GargPK, MaulikSK, et al.A randomized controlled trial of antioxidant supplementation for pain relief in patients with chronic pancreatitis. Gastroenterology2009;136:149. CrossRef

55. SiriwardenaAK, MasonJM, SheenAJ, et al.Antioxidant therapy does not reduce pain in patients with chronic pancreatitis: the ANTICIPATE study. Gastroenterology2012;143:655. CrossRef

56. DhingraR, SinghN, SachdevV, et al.Effect of antioxidant supplementation on surrogate markers of fibrosis in chronic pancreatitis: a randomized, placebo‐controlled trial. Pancreas2013;42:589. CrossRef

57. FregniF, PotvinK, DasilvaD, et al.Clinical effects and brain metabolic correlates in non‐invasive cortical neuromodulation for visceral pain. Eur J Pain2011;15:53. CrossRef

58. PetersonWL, FendrickAM, CaveDR, et al.Helicobacter pylori‐related disease: guidelines for testing and treatment. Arch Intern Med2000;160:1285. CrossRef

59. DiehlDL. Acupuncture for gastrointestinal and hepatobiliary disorders. J Altern Complement Med1999;5:27. CrossRef

60. LuxG, HagelJ, BackerP, et al.Acupuncture inhibits vagal gastric acid secretion stimulated by sham feeding in healthy subjects. Gut1994;35:1026. CrossRef

61. CoffinB, AzpirozF, MalageladaJR. Somatic stimulation reduces perception of gut distention in humans. Gastroenterology1994;107:1636. CrossRef

62. LinX, LiangJ, RenJ, et al.Electrical stimulation of acupuncture points enhances gastric myoelectrical activity in humans. Am J Gastroenterol1997;92:1527.

63. KokluS, KokluG, OzgucluE, et al.Clinical trial: interferential electric stimulation in functional dyspepsia patients – a prospective randomized study. Aliment Pharmacol Ther2010;31:961. CrossRef

64. ZengF, QinW, MaT, et al.Influence of acupuncture treatment on cerebral activity in functional dyspepsia patients and its relationship with efficacy. Am J Gastroenterol2012;107:1236. CrossRef

65. MaTT, YuSY, LiY, et al.Randomised clinical trial: an assessment of acupuncture on specific meridian or specific acupoint vs. sham acupuncture for treating functional dyspepsia. Aliment Pharmacol Ther2012;35:552. CrossRef

66. LimaFA, FerreiraLE, PaceFH. Acupuncture effectiveness as a complementary therapy in functional dyspepsia patients. Arq Gastroenterol2013;50:202. CrossRef

67. MalfertheinerP, MegraudF, O'MorainC, et al.Current concepts in the management of Helicobacter pylori infection–the Maastricht 2‐2000 Consensus Report. Aliment Pharmacol Ther2002;16:167. CrossRef

68. SheuBS, ChengHC, KaoAW, et al.Pretreatment with Lactobacillus‐ and Bifidobacterium‐containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. Am J Clin Nutr2006;83:864.

69. MillerMJ, MacNaughtonWK, ZhangXJ, et al.Treatment of gastric ulcers and diarrhea with the Amazonian herbal medicine sangre de grado. Am J Physiol Gastrointest Liver Physiol2000;279:G192.

70. MaLS, GuoTM. [Combined traditional Chinese and Western medicine in the treatment of intractable ulcer]. Zhongguo Zhong Xi Yi Jie He Za Zhi1992;12:524, 516.

71. WangXL, JiaoWL, LuZS. [Preliminary screening of Chinese herbal medicine in inhibiting Helicobacter pylori]. Zhongguo Zhong Xi Yi Jie He Za Zhi1994;14:534.

72. BorrelliF, IzzoAA. The plant kingdom as a source of anti‐ulcer remedies. Phytother Res2000;14:581. CrossRef

73. Thompson CoonJ, ErnstE. Systematic review: herbal medicinal products for non‐ulcer dyspepsia. Aliment Pharmacol Ther2002;16:1689. CrossRef

74. KoretzRL, RotblattM. Complementary and alternative medicine in gastroenterology: the good, the bad, and the ugly. Clin Gastroenterol Hepatol2004;2:957. CrossRef

75. BradenB, CasparyW, BornerN, et al.Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil2009;21:632, e25. CrossRef

76. MelzerJ, RoschW, ReichlingJ, et al.Meta‐analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther2004;20:1279. CrossRef

77. von ArnimU, PeitzU, VinsonB, et al.STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo‐controlled double‐blind study. Am J Gastroenterol2007;102:1268. CrossRef

78. ViladomiuM, HontecillasR, YuanL, et al.Nutritional protective mechanisms against gut inflammation. J Nutr Biochem2013;24:929. CrossRef

79. RoberfroidM. Prebiotics: the concept revisited. J Nutr2007;137:830S.

80. CummingsJH, MacfarlaneGT, EnglystHN. Prebiotic digestion and fermentation. Am J Clin Nutr2001;73:415S.

81. SchleyPD, FieldCJ. The immune‐enhancing effects of dietary fibres and prebiotics. Br J Nutr2002;87(Suppl 2):S221. CrossRef

82. MadsenKL, DoyleJS, JewellLD, et al.Lactobacillus species prevents colitis in interleukin 10 gene‐deficient mice. Gastroenterology1999;116:1107. CrossRef

83. GibsonGR, RoberfroidMB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr1995;125:1401.

84. SilkDB, DavisA, VulevicJ, et al.Clinical trial: the effects of a trans‐galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther2009;29:508. CrossRef

85. BouhnikY, VahediK, AchourL, et al.Short‐chain fructo‐oligosaccharide administration dose‐dependently increases fecal bifidobacteria in healthy humans. J Nutr1999;129:113.

86. SandersME. Use of probiotics and yogurts in maintenance of health. J Clin Gastroenterol2008;42(Suppl 2):S71. CrossRef

87. BoirivantM, StroberW. The mechanism of action of probiotics. Curr Opin Gastroenterol2007;23:679. CrossRef

88. HoveydaN, HeneghanC, MahtaniKR, et al.A systematic review and meta‐analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol2009;9:15. CrossRef

89. WhorwellPJ, AltringerL, MorelJ, et al.Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol2006;101:1581. CrossRef

90. O'MahonyL, McCarthyJ, KellyP, et al.Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology2005;128:541. CrossRef

91. GuyonnetD, ChassanyO, DucrotteP, et al.Effect of a fermented milk containing Bifidobacterium animalis DN‐173 010 on the health‐related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double‐blind, controlled trial. Aliment Pharmacol Ther2007;26:475. CrossRef

92. AgrawalA, HoughtonLA, MorrisJ, et al.Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN‐173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther2009;29:104. CrossRef

93. TakahashiT. Acupuncture for functional gastrointestinal disorders. J Gastroenterol2006;41:408. CrossRef

94. LimB, ManheimerE, LaoL, et al.Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev2006;(4):CD005111.

95. SchneiderA, EnckP, StreitbergerK, et al.Acupuncture treatment in irritable bowel syndrome. Gut2006;55:649. CrossRef

96. LemboAJ, ConboyL, KelleyJM, et al.A treatment trial of acupuncture in IBS patients. Am J Gastroenterol2009;104:1489. CrossRef

97. MadischA, HoltmannG, PleinK, et al.Treatment of irritable bowel syndrome with herbal preparations: results of a double‐blind, randomized, placebo‐controlled, multi‐centre trial. Aliment Pharmacol Ther2004;19:271. CrossRef

98. PittlerMH, ErnstE. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol1998;93:1131. CrossRef

99. HawthornM, FerranteJ, LuchowskiE, et al.The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther1988;2:101. CrossRef

100. MeratS, KhaliliS, MostajabiP, et al.The effect of enteric‐coated, delayed‐release peppermint oil on irritable bowel syndrome. Dig Dis Sci2010;55:1385. CrossRef

101. LiuJH, ChenGH, YehHZ, et al.Enteric‐coated peppermint‐oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol1997;32:765. CrossRef

102. KhannaR, MacDonaldJK, LevesqueBG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta‐analysis. J Clin Gastroenterol2014;48:505.

103. SallonS, Ben‐AryeE, DavidsonR, et al.A novel treatment for constipation‐predominant irritable bowel syndrome using Padma Lax, a Tibetan herbal formula. Digestion2002;65:161. CrossRef

104. BensoussanA, TalleyNJ, HingM, et al.Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA1998;280:1585. CrossRef

105. BianZ, WuT, LiuL, et al.Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review. J Altern Complement Med2006;12:401. CrossRef

106. PanF, ZhangT, ZhangYH, et al.Effect of Tongxie Yaofang Granule in treating diarrhea‐predominate irritable bowel syndrome. Chin J Integr Med2009;15:216. CrossRef

107. HartAL, StaggAJ, KammMA. Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol2003;36:111. CrossRef

108. LammersKM, VergopoulosA, BabelN, et al.Probiotic therapy in the prevention of pouchitis onset: decreased interleukin‐1beta, interleukin‐8, and interferon‐gamma gene expression. Inflamm Bowel Dis2005;11:447. CrossRef

109. IsolauriE, SutasY, KankaanpaaP, et al.Probiotics: effects on immunity. Am J Clin Nutr2001;73:444S.

110. SalminenS, BouleyC, Boutron‐RuaultMC, et al.Functional food science and gastrointestinal physiology and function. Br J Nutr1998;80(Suppl 1):S147. CrossRef

111. SwidsinskiA, LadhoffA, PernthalerA, et al.Mucosal flora in inflammatory bowel disease. Gastroenterology2002;122:44. CrossRef

112. MimuraT, RizzelloF, HelwigU, et al.Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut2004;53:108. CrossRef

113. SchultzM. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis2008;14:1012. CrossRef

114. ShenJ, ZuoZX, MaoAP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta‐analysis of randomized controlled trials. Inflamm Bowel Dis2014;20:21. CrossRef

115. KatoK, MizunoS, UmesakiY, et al.Randomized placebo‐controlled trial assessing the effect of bifidobacteria‐fermented milk on active ulcerative colitis. Aliment Pharmacol Ther2004;20:1133. CrossRef

116. KruisW, SchutzE, FricP, et al.Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther1997;11:853. CrossRef

117. RembackenBJ, SnellingAM, HawkeyPM, et al.Non‐pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet1999;354:635. CrossRef

118. BibiloniR, FedorakRN, TannockGW, et al.VSL#3 probiotic‐mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol2005;100:1539. CrossRef

119. MieleE, PascarellaF, GiannettiE, et al.Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol2009;104:437. CrossRef

120. SoodA, MidhaV, MakhariaGK, et al.The probiotic preparation, VSL#3 induces remission in patients with mild‐to‐moderately active ulcerative colitis. Clin Gastroenterol Hepatol2009;7:1202, 1209 e1. CrossRef

121. HuynhHQ, deBruynJ, GuanL, et al.Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis2009;15:760. CrossRef

122. ParkKT, PerezF, TsaiR, et al.Cost‐effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr2011;53:489.

123. SchultzM, TimmerA, HerfarthHH, et al.Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol2004;4:5. CrossRef

124. MalchowHA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?J Clin Gastroenterol1997;25:653. CrossRef

125. GuslandiM, MezziG, SorghiM, et al.Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci2000;45:1462. CrossRef

126. BourreilleA, CadiotG, Le DreauG, et al.Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol2013;11:982. CrossRef

127. ElliottDE, UrbanJJ, ArgoCK, et al.Does the failure to acquire helminthic parasites predispose to Crohn's disease?FASEB J2000;14:1848. CrossRef

128. MosmannTR, CherwinskiH, BondMW, et al.Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol1986;136:2348.

129. RomagnaniS. Lymphokine production by human T cells in disease states. Annu Rev Immunol1994;12:227. CrossRef

130. LeungJ, HangL, BlumA, et al.Heligmosomoides polygyrus abrogates antigen‐specific gut injury in a murine model of inflammatory bowel disease. Inflamm Bowel Dis2012;18:1447. CrossRef

131. ElliottDE, LiJ, BlumA, et al.Exposure to schistosome eggs protects mice from TNBS‐induced colitis. Am J Physiol Gastrointest Liver Physiol2003;284:G385. CrossRef

132. SummersRW, ElliottDE, UrbanJFJr, et al.Trichuris suis therapy in Crohn's disease. Gut2005;54:87. CrossRef

133. SummersRW, ElliottDE, UrbanJFJr, et al.Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology2005;128:825. CrossRef

134. SandbornWJ, ElliottDE, WeinstockJ, et al.Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Aliment Pharmacol Ther2013;38:255. CrossRef

135. VinoloMA, RodriguesHG, NachbarRT, et al.Regulation of inflammation by short chain fatty acids. Nutrients2011;3:858. CrossRef

136. HamerHM, JonkersDM, VanhoutvinSA, et al.Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin Nutr2010;29:738. CrossRef

137. Fernandez‐BanaresF, HinojosaJ, Sanchez‐LombranaJL, et al.Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol1999;94:427. CrossRef

138. KanauchiO, MitsuyamaK, HommaT, et al.Treatment of ulcerative colitis patients by long‐term administration of germinated barley foodstuff: multi‐center open trial. Int J Mol Med2003;12:701.

139. KanauchiO, SugaT, TochiharaM, et al.Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol2002;37(Suppl 14):67. CrossRef

140. HiguchiLM, KhaliliH, ChanAT, et al.A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol2012;107:1399. CrossRef

141. SutherlandLR, RamcharanS, BryantH, et al.Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology1990;98:1123.

142. BoykoEJ, KoepsellTD, PereraDR, et al.Risk of ulcerative colitis among former and current cigarette smokers. N Engl J Med1987;316:707. CrossRef

143. BeaugerieL, MassotN, CarbonnelF, et al.Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol2001;96:2113. CrossRef

144. PullanRD, RhodesJ, GaneshS, et al.Transdermal nicotine for active ulcerative colitis. N Engl J Med1994;330:811. CrossRef

145. SandbornWJ, TremaineWJ, OffordKP, et al.Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double‐blind, placebo‐controlled trial. Ann Intern Med1997;126:364. CrossRef

146. IngramJR, RhodesJ, EvansBK, et al.Preliminary observations of oral nicotine therapy for inflammatory bowel disease: an open‐label phase I‐II study of tolerance. Inflamm Bowel Dis2005;11:1092. CrossRef

147. IngramJR, ThomasGA, RhodesJ, et al.A randomized trial of nicotine enemas for active ulcerative colitis. Clin Gastroenterol Hepatol2005;3:1107. CrossRef

148. MacDonaldTT, BellI, MonteleoneG. The opposing roles of IL‐21 and TGFbeta1 in chronic inflammatory bowel disease. Biochem Soc Trans2011;39:1061. CrossRef

149. SmythCM, AkashehN, WoodsS, et al.Activated eosinophils in association with enteric nerves in inflammatory bowel disease. PLoS ONE2013;8:e64216. CrossRef

150. FellJM, PaintinM, Donnet‐HughesA, et al.Remission induced by a new specific oral polymeric diet in children with Crohn's disease. Nestle Nutr Workshop Ser Clin Perform Programme1999;2:187; discussion 196. CrossRef

151. OzHS, RayM, ChenTS, et al.Efficacy of a transforming growth factor beta 2 containing nutritional support formula in a murine model of inflammatory bowel disease. J Am Coll Nutr2004;23:220. CrossRef

152. HamadyZZ, ScottN, FarrarMD, et al.Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF‐beta1 under the control of dietary xylan 1. Inflamm Bowel Dis2011;17:1925. CrossRef

153. YangF, OzHS, BarveS, et al.The green tea polyphenol (‐)‐epigallocatechin‐3‐gallate blocks nuclear factor‐kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC‐6. Mol Pharmacol2001;60:528.

154. OzHS, ChenT, de VilliersWJ. Green tea polyphenols and sulfasalazine have parallel anti‐inflammatory properties in colitis models. Front Immunol2013;4:132.

155. OzHS, ChenTS, McClainCJ, et al.Antioxidants as novel therapy in a murine model of colitis. J Nutr Biochem2005;16:297. CrossRef

156. SharonP, StensonWF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology1984;86:453.

157. HawthorneAB, DaneshmendTK, HawkeyCJ, et al.Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut1992;33:922. CrossRef

158. BelluzziA, BrignolaC, CampieriM, et al.Effect of an enteric‐coated fish‐oil preparation on relapses in Crohn's disease. N Engl J Med1996;334:1557. CrossRef

159. RomanoC, CucchiaraS, BarabinoA, et al.Usefulness of omega‐3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double‐blind, randomized, placebo‐controlled study. World J Gastroenterol2005;11:7118. CrossRef

160. FeaganBG, SandbornWJ, MittmannU, et al.Omega‐3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA2008;299:1690. CrossRef

161. TurnerD, ZlotkinSH, ShahPS, et al.Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev2009;(1):CD006320.

162. TurnerD, ShahPS, SteinhartAH, et al.Maintenance of remission in inflammatory bowel disease using omega‐3 fatty acids (fish oil): a systematic review and meta‐analyses. Inflamm Bowel Dis2011;17:336. CrossRef

163. GuptaI, PariharA, MalhotraP, et al.Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med2001;67:391. CrossRef

164. HoltmeierW, ZeuzemS, PreissJ, et al.Randomized, placebo‐controlled, double‐blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy. Inflamm Bowel Dis2011;17:573. CrossRef

165. ArafaHM, HemeidaRA, El‐BahrawyAI, et al.Prophylactic role of curcumin in dextran sulfate sodium (DSS)‐induced ulcerative colitis murine model. Food Chem Toxicol2009;47:1311. CrossRef

166. KumarS, AhujaV, SankarMJ, et al.Curcumin for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev2012;(10):CD008424.

167. HoltPR, KatzS, KirshoffR. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci2005;50:2191. CrossRef

168. HanaiH, IidaT, TakeuchiK, et al.Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double‐blind, placebo‐controlled trial. Clin Gastroenterol Hepatol2006;4:1502. CrossRef

169. BarbutF, MeynardJL. Managing antibiotic associated diarrhoea. BMJ2002;324:1345. CrossRef

170. HempelS, NewberrySJ, MaherAR, et al.Probiotics for the prevention and treatment of antibiotic‐associated diarrhea: a systematic review and meta‐analysis. JAMA2012;307:1959. CrossRef

171. AllenSJ, WarehamK, WangD, et al.Lactobacilli and bifidobacteria in the prevention of antibiotic‐associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double‐blind, placebo‐controlled, multicentre trial. Lancet2013;382:1249. CrossRef

172. SelingerCP, BellA, CairnsA, et al.Probiotic VSL#3 prevents antibiotic‐associated diarrhoea in a double‐blind, randomized, placebo‐controlled clinical trial. J Hosp Infect2013;84:159. CrossRef

173. ApplegateJA, Fischer WalkerCL, AmbikapathiR, et al.Systematic review of probiotics for the treatment of community‐acquired acute diarrhea in children. BMC Public Health2013;13(Suppl 3):S16. CrossRef

174. DubeyAP, RajeshwariK, ChakravartyA, et al.Use of VSL[sharp]3 in the treatment of rotavirus diarrhea in children: preliminary results. J Clin Gastroenterol2008;42(Suppl 3):S126. CrossRef

175. ChenCC, KongMS, LaiMW, et al.Probiotics have clinical, microbiologic, and immunologic efficacy in acute infectious diarrhea. Pediatr Infect Dis J2010;29:135. CrossRef

176. HuangYF, LiuPY, ChenYY, et al.Three‐combination probiotics therapy in children with salmonella and rotavirus gastroenteritis. J Clin Gastroenterol2014;48:37. CrossRef

177. AllenSJ, MartinezEG, GregorioGV, et al.Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev2010;(11):CD003048.

178. RabbaniGH, TekaT, ZamanB, et al.Clinical studies in persistent diarrhea: dietary management with green banana or pectin in Bangladeshi children. Gastroenterology2001;121:554. CrossRef

179. EnglystHN, CummingsJH. Digestion of the carbohydrates of banana (Musa paradisiaca sapientum) in the human small intestine. Am J Clin Nutr1986;44:42.

180. RabbaniGH, AlbertMJ, Hamidur RahmanAS, et al.Short‐chain fatty acids improve clinical, pathologic, and microbiologic features of experimental shigellosis. J Infect Dis1999;179:390. CrossRef

181. SubbotinaMD, TimchenkoVN, VorobyovMM, et al.Effect of oral administration of tormentil root extract (Potentilla tormentilla) on rotavirus diarrhea in children: a randomized, double blind, controlled trial. Pediatr Infect Dis J2003;22:706. CrossRef

182. KugeT, ShibataT, WillettMS. Multicenter, double‐blind, randomized comparison of wood creosote, the principal active ingredient of Seirogan, an herbal antidiarrheal medication, and loperamide in adults with acute nonspecific diarrhea. Clin Ther2004;26:1644. CrossRef

183. MacarthurRD, HawkinsTN, BrownSJ, et al.Efficacy and safety of crofelemer for noninfectious diarrhea in HIV‐seropositive individuals (ADVENT trial): a randomized, double‐blind, placebo‐controlled, two‐stage study. HIV Clin Trials2013;14:261. CrossRef

184. TroisL, CardosoEM, MiuraE. Use of probiotics in HIV‐infected children: a randomized double‐blind controlled study. J Trop Pediatr2008;54:19. CrossRef

185. Gonzalez‐HernandezLA, Jave‐SuarezLF, Fafutis‐MorrisM, et al.Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV‐infected patients: a double‐blind randomized controlled pilot trial. Nutr J2012;11:90. CrossRef

186. ChangBH, SommersE. Acupuncture and the relaxation response for treating gastrointestinal symptoms in HIV patients on highly active antiretroviral therapy. Acupunct Med2011;29:180. CrossRef

187. CarcamoC, HootonT, WeissNS, et al.Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV‐1 infection. J Acquir Immune Defic Syndr2006;43:197. CrossRef

188. ConteasCN, PanossianAM, TranTT, et al.Treatment of HIV‐associated diarrhea with curcumin. Dig Dis Sci2009;54:2188. CrossRef

189. BunchorntavakulC, ReddyKR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther2013;37:3. CrossRef

190. AngellM, KassirerJP. Alternative medicine–the risks of untested and unregulated remedies. N Engl J Med1998;339:839. CrossRef

191. LekehalM, PessayreD, LereauJM, et al.Hepatotoxicity of the herbal medicine germander: metabolic activation of its furano diterpenoids by cytochrome P450 3A Depletes cytoskeleton‐associated protein thiols and forms plasma membrane blebs in rat hepatocytes. Hepatology1996;24:212. CrossRef

192. ShawD, LeonC, KolevS, et al.Traditional remedies and food supplements. A 5‐year toxicological study (1991‐1995). Drug Saf1997;17:342. CrossRef

193. CuiJ, GarleM, EnerothP, et al.What do commercial ginseng preparations contain?Lancet1994;344:134. CrossRef

194. KoRJ. Adulterants in Asian patent medicines. N Engl J Med1998;339:847.

195. KaplowitzN. Hepatotoxicity of herbal remedies: insights into the intricacies of plant‐animal warfare and cell death. Gastroenterology1997;113:1408. CrossRef

196. SchuppanD, JiaJD, BrinkhausB, et al.Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology1999;30:1099. CrossRef

197. BeigelY, OstfeldI, SchoenfeldN. Clinical problem‐solving. A leading question. N Engl J Med1998;339:827. CrossRef

198. SlifmanNR, ObermeyerWR, AloiBK, et al.Contamination of botanical dietary supplements by Digitalis lanata. N Engl J Med1998;339:806. CrossRef

199. NavarroVJ, SeeffLB. Liver injury induced by herbal complementary and alternative medicine. Clin Liver Dis2013;17:715, x. CrossRef

200. ShiJ, TongY, ShenJG, et al.Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: a systematic review. World J Gastroenterol2008;14:454. CrossRef

201. LeeA, ChuiPT, AunCS, et al.Incidence and risk of adverse perioperative events among surgical patients taking traditional Chinese herbal medicines. Anesthesiology2006;105:454. CrossRef

202. WhinneyC. Perioperative medication management: general principles and practical applications. Cleve Clin J Med2009;76(Suppl 4):S126. CrossRef

203. RuschitzkaF, MeierPJ, TurinaM, et al.Acute heart transplant rejection due to Saint John's wort. Lancet2000;355:548. CrossRef

204. PiscitelliSC, BursteinAH, ChaittD, et al.Indinavir concentrations and St John's wort. Lancet2000;355:547. CrossRef